Sign up
Pharma Capital

SkinBioTherapeutics sees flagship technology take critical next step

Dr Catherine O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), updates Proactive on progress with their platform - saying it's passed a key safety test.

The SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

No cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration.

The data backed up in-house results compiled by the company, which listed on the stock market in April.

 

View full SBTX profile

SkinBioTherapeutics PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.